key: cord-0872759-hfbodtub
authors: Huang, Kai; Zhang, Pan; Zhang, Zhenghao; Youn, Ji Youn; Zhang, Hongchun; Cai, Hua Linda
title: Traditional Chinese Medicine (TCM) in the treatment of viral infections: Efficacies and mechanisms
date: 2021-03-31
journal: Pharmacol Ther
DOI: 10.1016/j.pharmthera.2021.107843
sha: a6796aae6d1c6597905c7775015062742208b2a8
doc_id: 872759
cord_uid: hfbodtub

COVID-19 has remained an uncontained, worldwide pandemic. While battling for the disease in China, six Traditional Chinese Medicine (TCM) recipes have been shown to be remarkably effective for treating patients with COVID-19. The present review discusses principles of TCM in curing infectious disease, and clinical evidence and mechanisms of the 6 most effective TCM recipes used in treating COVID-19 in 92% of all of the confirmed cases in China. Applications of TCM and specific recipes in the treatment of other viral infections, such as those caused by SARS-CoV, MERS-CoV, hepatitis B virus, hepatitis C virus, influenza A virus (including H1N1 and H7N9), influenza B, dengue virus as well as Ebola virus, are also discussed. Among the 6 TCM recipes, Jinhua Qinggan (JHQG) granules and Lianhua Qingwen (LHQW) capsules are recommended during medical observation; Lung Cleansing and Detoxifying Decoction (LCDD) is recommended for the treatment of both severe and non-severe patients; Xuanfeibaidu (XFBD) granules are recommended for treating moderate cases; while Huashibaidu (HSBD) and Xuebijing (XBJ) have been used in managing severe cases effectively. The common components and the active ingredients of the six TCM recipes have been summarized to reveal most promising drug candidates. The potential molecular mechanisms of the active ingredients in the six TCM recipes that target ACE2, 3CL(pro) and IL-6, revealed by molecular biological studies and/or network pharmacology prediction/molecular docking analysis/visualization analysis, are fully discussed. Therefore, further investigation of these TCM recipes may be of high translational value in revealing novel targeted therapies for COVID-19, potentially via purification and characterization of the active ingredients in the effective TCM recipes.

COVID-19 has remained an uncontained, worldwide pandemic. During the fight against the disease in China, the National Health Commission China declared that 92% of the confirmed COVID-19 cases were treated with Traditional Chinese Medicine (TCM) in combination with Western Medicine, and the patients responded to the treatment to recover or much improve in more than 90% of the cases (ChinaDaily, 2020b) . For patients with mild and moderate disease, early intervention with TCM has been shown to effectively prevent disease transition into severe and critical state . In the severe cases, TCM has helped to stabilize the patients for prolonged therapeutic window (J. L. . Accumulating evidence has shown that early intervention of COVID-19 patients with TCM is important in improving cure rate, shortening the course of disease, delaying disease progression and reducing mortality rate(J. L. . The current review discusses efficacies and mechanisms of TCM recipes that have proven to be robustly effective in treating patients with COVID-19 in China, milestones of TCM applications in treating infectious disease through the long history of China, as well as applications and efficacies of TCM in treating other types of viral infections including those caused by SARS-CoV, MERS-CoV, hepatitis B virus, hepatitis C virus, influenza A virus (including H1N1 and H7N9), influenza B, dengue virus as well as Ebola virus.

Historically, TCM has worked well in treating infectious disease ( Figure 1 ). During the past 3,000 years of Chinese history, TCM has been used as the routine treatment regime for pandemic and endemic diseases. In dealing with these, a complete theoretical system of prevention and concepts were described including holistic theory (整体观念), yin and yang and five elements theory (阴阳五行), visceral meridian theory (脏象经络), etiology and pathogenesis theory (病因病 机), diagnosis and therapy theory (诊法治则), prevention and health care theory (预防养生) and doctrine of "Qi" (运气学说) (Curran, 2008; Luo, Tang, et al., 2020) (Figure 1 ). The classical TCM book named Shanghan Lun (Treatise on Cold Damage Diseases as the translation, simplified Chinese: 伤寒论) describes a system of characterizing the disease by six main syndromes, with characteristic symptoms and pulses to guide diagnosis and appropriate individualized prescriptions for treatment; this book lays foundation for differential syndrome categorization and individualized treatment in TCM, especially for infectious disease. A book named Zhou hou bei ji fang, ("Emergency Prescriptions kept in one's Sleeve", simplified Chinese: 肘后备急方) written by Ge Hong, describes TCM applications for treating malaria. The specific instructions of treatment in this book are the followings: 'Immerse a handful of Qing Hao (青蒿) in two liters of water, wring out the juice and drink it all (青蒿一握, 以水二升渍, 绞取汁, 尽服之)' (Tu, 2015) . This has inspired Professor Youyou Tu (Chinese name: 屠呦呦) to isolate artemisinin from Qing Hao (青蒿) with ether, and discover its therapeutic effects on Malaria, which later claimed the 2015 Nobel Prize in Physiology and Medicine (Tu, 2015) .

Formulated Chinese medicine has been used in managing previous pandemics, such as the two previous coronavirus outbreaks involving SARS-CoV in 2003 and MERS-CoV in 2012, and  seasonal epidemics caused by influenza viruses and dengue virus(H. . During the 2002-2003 SARS (Severe Acute Respiratory Syndrome) epidemic in China, TCM was used in the prevention (Lau, et al., 2005) and treatment of SARS(Z. Chen & Nakamura, 2004) , which had been shown to result in shorter hospitalization, reduced side effects from steroid treatments, and relief from dyspnoea and malaise (WHO, 2004) . To date, dozens of Chinese herbs and hundreds of natural TCM ingredients have been reported to possess antiviral activities .

Journal Pre-proof TCM have been shown to possess antiviral activities against various viral strains including herpes simplex virus, influenza virus, human immunodeficiency virus, hepatitis B and C viruses, and SARS-CoV and MERS-CoV . When the human transmissible swine flu virus (H1N1) was reported in Mexico and the United States in April 2009, the Chinese government rapidly released three editions of documents entitled "Recommended Schemes for Pandemic Influenza A Diagnoses and Treatments" (Ge, et al., 2010) . Besides the two targeted anti-flu drugs, Oseltamivir and Zanamivir, four anti-flu TCM prescriptions were recommended for the treatment of H1N1 infection in the third edition (Ge, et al., 2010) . A meta-analysis of 30 studies including 3,444 cases indicates that the mean time to defervescence in the TCM treatment group was significantly reduced, and that the duration of viral [Influenza A (H1N1)] shedding in the subgroup of patients receiving integrated treatment of Chinese and Western medicine, was also significantly shortened(J. H. .

TCM drugs are traditionally composed of many different herbs/components with known or unknown active ingredients that can target various pathways for a given class of medical indications, and are tunable to the symptoms of an individual (Ge, et al., 2010) . The evidence-based guideline on treating adult influenza patients with TCM has been developed (L. Wu, et al., 2020) . Earlier work by Wu et al. formulated six recommendations based on evidence synthesis and experts' consensus, namely Lianhua Qingwen capsule (LHQW,连花清瘟胶囊), Jinhua Qinggan granule (JHQG,金花清感颗粒), Banlangen granule (BLG,板蓝根颗粒), Shufeng medicine-active ingredients-target network (Jimilihan, et al., 2020) .

The protein-protein interaction (PPI) analysis of the targets was carried out by String (https://string-db.org/) database, and the potential targets of the active ingredients were identified (Jimilihan, et al., 2020) . The potential targets were subsequently analyzed for gene function by ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology (GO) and pathway annotation networks (Bindea, et al., 2009; Dennis, et al., 2003; Jimilihan, et al., 2020; Kanehisa & Goto, 2000) . The targets can also be analyzed by DAVID (Database for Annotation, Visualization, and Integrated Discovery, a web-accessible program that integrates functional genomics annotations with intuitive graphical summaries) following identification of Kyoto Encyclopedia of Genes and Genomes (KEGG, a knowledge base for systematic analysis of gene functions, linking genomic information with higher order functional information) signaling pathways (Bindea, et al., 2009; Dennis, et al., 2003; Jimilihan, et al., 2020; Kanehisa & Goto, 2000) . Liu, et al., 2020) .

JHQG granules (金花清感颗粒) was specifically formulated for treating influenza A (H1N1) by the expert group of TCM after the 2009 H1N1 influenza outbreak in Mexico (Qi, Qi, & Wang, 2016) . JHQG recipe was found highly effective for treating H1N1 infection in animal models and clinical studies before the recipe became widely used (Yan, 2010) . In one preclinical study, JHQG was found to markedly decrease mortality and improve survival, while reducing the severity of pulmonary lesions in mice infected with H1N1 virus (Yan, 2010) . In another study, JHQG was able to reduce fever and inflammation in a rabbit model of H1N1 infection (Yan, 2010) . In addition, a clinical study showed that JHQG markedly reduced duration of fever and alleviated symptoms (Yan, 2010) . In a double-blinded, randomized controlled trial (RCT) of 136 influenza patients, JHQG (5 g each time, three times daily for 5 days) speeded up recovery of the patients(G. Q. Li, et al., 2013) .

In another double-blinded RCT of 174 influenza patients, the same dose of JHQG also significantly reduced serum levels of CRP and IFN-γ (Qi, et al., 2016) .

JHQG has proven to be an effective treatment for COVID-19, after being selected by joint efforts of Chinese and Western medical experts organized by Beijing Administration of Traditional Chinese Medicine, referring to more than 100 ancient prescriptions in TCM classics such as Treatise on Febrile Diseases (伤寒论), Wenyi Lun (瘟疫论) and Wenbing Tiaobian (温病条辨)(Z. Liu, et al., 2020) . Accumulating evidence has demonstrated that JHQG significantly alleviated clinical symptoms of mild COVID-19 patients, such as fever, cough, fatigue, and expectoration, and can relieve anxiety of the patients . Liu et al. reported that 7-day viral clearance rate was significantly higher while pneumonia recovery time was significantly shorter in J o u r n a l P r e -p r o o f the JHQG treated group, in a study of 80 COVID-19 cases (Z. Liu, et al., 2020) . Furthermore, in a case control study of 123 patients with COVID-19, JHQG significantly relieved symptoms of fever, cough, fatigue and anxiety in patients with mild COVID-19 (Shen, et al.) . The chemical constituents and molecular targets of the 12 components in JHQG have been identified using TCMSP (as described above). UniProt explain was used to search for the targets of the JHQG's ingredients, and Cytoscape 3.7.2 was used to construct the ingredients-target (gene) network. DAVID was used to perform enrichment analysis of GO functions and the KEGG pathways to predict the mechanisms of action. Cytoscape 3.7.2 based analyses indicate that the major active ingredients (including chlorogenic acid, forsythoside A, and ephedrine) of JHQG were found to dock with 3CL pro , SARS-CoV-2 spike glycoprotein (S protein), ACE2, and suppressor of cytokine signaling 1 (SOCS1)(Y. Ren, Z. Yin, et al., 2020) .

Visualization analysis with DAVID demonstrated that the core active ingredients of JHQG have strong affinity for 3CL pro , S protein, ACE2, and SOCS1, thereby inhibiting virus replication and binding to target cells, reducing host inflammation and activating antiviral immunity(Y. Ren, Z. Yin, et al., 2020) . Network pharmacology and molecular docking analyses performed by Gong et al. indicate that the effective compounds in JHQG regulate multiple signaling pathways via binding to ACE2, involving Prostaglandin-endoperoxide synthase 1 (PTGS1), Prostaglandin-endoperoxide synthase 2 (PTGS2), Heat shock protein HSP 90-alpha (HSP90AA1), Heat shock protein HSP 90-beta (HSP90AB1), and Nuclear receptor coactivator 2 (NCOA2) (Gong, Guo, Li, Wang, & Gu, 2020 ). In addition, Simayi et al. elucidated that the active ingredients of JHQG, such as kaempferol, baicalein and oroxylin A, regulate multiple signaling pathways (such as PTGS2, B-cell lymphoma 2(BCL2) and Caspase-3) by binding to ACE2 (Jimilihan, et al., 2020) . More detailed J o u r n a l P r e -p r o o f discussion of target pathways driven by specific active ingredients of JHQG and other TCM recipes is included in Section 3. Dryopteridis Crassirhizomatis Rhizoma) (Ding, et al., 2017; Z. Tao, et al., 2013) .

LHQW capsules (连花清瘟胶囊) was patented in 2003 in China, and was approved for Phase II clinical trial by US FDA in 2015 (Ye, et al.) . It has been used to treat influenza and shown to have broad-spectrum antiviral effects on a number of influenza viruses with immune regulatory effects (Ding, et al., 2017; Z. Tao, et al., 2013) . A meta-analysis of RCT revealed that LHQW treatment in patients infected with influenza A virus resulted in shorter duration of fever, cough, sore throat, and body ache, comparing to Oseltamivir (anti-viral drug) treated patients (Zhao, Yang, Lv Yang, et al., 2020) . Of note, it has been shown that fewer inflammatory cells were present in the lungs of influenza B virus infected mice treated with LHQW(C. Yang, et al., 2020) . LHQW treated mice of influenza A virus (H1N1) infection had decreased virus replication, inflammation, and lung lesions(D. Gao, et al., 2020) .

Notably, Cyclooxygenase-2 (COX-2) was validated as a viable pharmacological biomarker for the treatment efficacy of LHQW, since low-and high-doses of LHQW decreased COX-2 expression while the high dose of LHQW was more effective than the low dose in H1N1 influenza virus infected mice (D. Gao, et al., 2020) . Besides, LHQW displayed a significant inhibitory effect on COX-2 activity in vitro in a dose-dependent manner (D. Gao, et al., 2020) . In addition, LHQW inhibited proliferation of influenza viruses of various strains in vitro in Madin-Darby canine kidney cells (Ding, et al., 2017) . It also blocked the early stages (0-2 h) of virus infection, suppressed virus-induced NF-kB activation and alleviated virus-induced gene expression of Interleukin-6 (IL-6), IL-8, tumor necrosis factor (TNF)-α, IP-10, and monocyte chemotactic protein 1(MCP-1) in a dose-dependent manner (1.5-3mg/mL) (Ding, et al., 2017) . Additionally, the viral titers and the levels of inflammatory cytokines were both decreased by LHQW administration (1300 mg/kg/day for 5 days) in the lungs of the mice inoculated with variant of H1N1 influenza virus A/PR/8/34 (H1N1) (H274Y mut) (Ding, et al., 2017) .

LHQW has been recommended by the Evidence-Based Medicine Chapter of the China International Exchange and Promotive Association for Medical and Health Care (CPAM) and the Chinese Research Hospital Association (CRHA) to treat patients with mild or moderate COVID-19

in combination with conventional therapy, which refers to respiratory support, symptomatic J o u r n a l P r e -p r o o f treatment, antiviral treatment, and antibacterial treatment if needed . A retrospective analysis of clinical records showed that fever was better resolved and fever duration was shortened in patients treated with LHQW plus conventional therapy (21 confirmed COVID-19 patients), compared to conventional therapy alone (21 confirmed COVID-19 patients) . Results from a retrospective analysis of 54 COVID-19 patients indicate that LHQW is effective in significantly relieving symptoms of fever, cough and weakness, and in shortening duration of having these symptoms(D. . Another RCT of mild COVID-19 patients showed that, compared with Arbidol (anti-influenza drug) treatment group of 148 patients, the total effective rate and the TCM syndrome scores (based on the TCM syndrome rating scale) were significantly improved after 7 day treatment with LHQW (6 g each time, three times daily) plus Arbidol in 147 patients (Yu, Li, Wan, & Wang, 2020) . LHQW combined with Arbidol more effectively alleviated clinical symptoms and improved treatment efficacy in patients with mild COVID-19 . Besides, a study of 151 severe COVID-19 patients indicated that quadruple combination therapy of LHQW, Ribavirin, Lopinavir/ritonavir and Umifenovir may serve as a preferred protocol for treating severe COVID-19 patients (X. . This combination of LHQW with three drugs may result in maximal suppression of viral replication and infection through different mechanisms of action(X. . Additionally, a study of 283 COVID-19 patients indicated that LHQW combined with Huoxiang Zhengqi dropping pills (HXZQ, 藿香正气滴丸) have advantages in the treatment of nausea, vomiting and limb soreness(M. Xiao, et al., 2020) . The combination of LHQW with HXZQ reduced the use of macrolides antibiotics and the number of diagnosed patients progressing into severe disease(M. Xiao, et al., 2020) . A prospective multicenter RCT of 284 COVID-19 patients indicate that clinical cure rate and the rate of recovery of chest CT manifestations were markedly higher in the patient group treated with LHQW (4 capsules thrice daily for 14 days)(K. .

Results from a recent meta-analysis of 154 COVID-19 patients indicate that the main clinical symptoms of fever, cough and fatigue disappeared faster in LHQW treated group; and that other symptoms of runny nose, sputum, nasal congestion, muscle pain, difficulty breathing, chest J o u r n a l P r e -p r o o f tightness, nausea and vomiting, and loss of appetite also disappeared faster while the duration of fever was significantly reduced by LHQW treatment . In addition, Hu et al.

evaluated the efficacy of LHQW in the treatment of common pneumonia and COVID-19

pneumonia by meta analysis of 42 studies involving 3,793 subjects, in which LHQW treatment was found associated with improvements in flu-like symptoms and conversion of severe cases(C. . Ultra performance liquid chromatography coupled with diode-array detector and quadrupole time-of-flight mass spectrometry (UPLC-DAD-QTOF-MS) was employed for qualitative and quantitative analyses of the major ingredients of LHQW, among which a total of 61 ingredients including flavonoids, phenylpropanoids, anthraquinones, triterpenoids, iridoids, and other types of compounds were unambiguously or tentatively identified by comparing the retention times and the accurate mass measurements with reference compounds and/or data in the literatures (Jia, et al., 2015) . Among them, twelve representative ingredients, including salidroside, chlorogenic acid, forsythoside E, cryptochlorogenic acid, amygdalin, sweroside, hyperin, rutin, forsythoside A, phillyrin, rhein, and glycyrrhizic acid were further quantified (Jia, et al., 2015) . In another study, the primary active ingredients of LHQW were identified by network pharmacology analysis, with a focus on 61 candidate ingredients to further identify their related targets (C. H. Wang, et al., 2016) . The main effective ingredient-target (MECT) network was constructed to reveal the main effective ingredients and their key targets for LHQW (C. H. Wang, et al., 2016) . It has been shown that the docking scores to 3CL pro of SARS-CoV-2 of three ingredients in LHQW, rutin, forsythoside E, and hyperoside, are better than that of Lopinavir (anti-viral drug) (Ye, et al.) .

In addition, at molecular levels, Li et al observed that LHQW significantly inhibited SARS-CoV-2 replication in Vero E6 cells, and markedly reduced mRNA expression of pro-inflammatory cytokines of TNF-α, IL-6, CCL-2/MCP-1 and CXCL-10/IP-10(R. 

Similar to XFBD above, HSBD (化湿败毒颗粒) was also specifically formulated for treating 

Treatment of COVID-19 patients with HSBD (化湿败毒颗粒) have been optimized based on clinical practice at Wuhan Jinyintan Hospital, one of the major sites caring for the COVID-19

patients (Wu, 2020) . It has been used for the treatment of mild, moderate and severe cases (Wu, 2020) . Recently, HSBD was approved by the United Arab Emirates health authorities and listed as a registered emergency drug for treating COVID-19 (Wu, 2020) . HSBD has been shown to be effective in significantly shortening the time to nucleic acid turning negative in patients with COVID-19(Q. Li, et al., 2020) . In addition, it can reduce the average length of hospitalization, and significantly improve clinical symptoms and pulmonary CT findings (Q. . In a study of 60 patients, HSBD (137 g, twice per day) strengthened the efficacy of Lopinavir-Ritonavir in the treatment of COVID-19(N. Shi, Guo, et al., 2020) . Besides, HSBD was found to reduce viral load in lung tissues by 30% in a mouse model (Q. . It has been shown that HSBD has anti-inflammatory, anti-viral and immune-modulating effects (Lai, et al.) . Xie et al. explored the potential mechanisms of HSBD in treating COVID-19 using network pharmacology and molecular docking analyses, from which 269 active ingredients and 2,629 drug targets were retrieved . The GO functional enrichment analysis indicate that lipopolysaccharide, reactive oxygen species (ROS) and

interferon-gamma-mediated signaling pathways are likely inhibited by HSBD in the treatment of COVID-19 . KEGG pathway enrichment analysis indicate that modulations of AGE-RAGE, TNFE, NFkB, and RIG-I-like receptor signaling pathways might be involved in mediating therapeutic effects of HSBD on COVID-19 . 

After being approved in 2003 by The National Medical Products Administration (NMPA) (Chinese:

国家药品监督管理局) (formerly the China Food and Drug Administration, or CFDA), XBJ injection has been used to treat infections caused by H1N1, H7N9, MERS, Ebola virus and dengue virus (Tong, Wu, Ni, Shen, & Liu, 2020) . XBJ has been frequently used as an add-on therapy to treat sepsis or septic shock and has been shown to attenuate inflammation and bacteriostasis without side effects (Fan, Cheng, Fang, Chen, & Su, 2020; Y. Gao, Chai, & Yao, 2013; R. Zheng, et al., 2019) . The combination of XBJ with Western Medicine Ulinastatin (UTI, an urinary trypsin inhibitor, commonly used as a drug to treat acute inflammatory disorders) was reported to be more effective than UTI alone in treating septic patients(S. H. Xiao, et al., 2018) . In addition, the combined therapy not only drastically reduced the 28-day mortality rate, mechanical ventilation time, length of ICU stay, occurrence rate of multiple organ dysfunction syndrome, and the acute physiology and chronic health evaluation score (APACHE II, a commonly used severity-of-disease classification system), but also decreased levels of procalcitonin (PCT), TNF-α, and IL-6(S. H.

J o u r n a l P r e -p r o o f Xiao, et al., 2018) . In a multi-center RCT of 710 critically-ill patients with severe community-acquired pneumonia, XBJ (100 mL, every12 hours, for at least 5 days up to a maximum of 7 days in adult patients) was found effective in improving survival rate, while shortening duration of mechanical ventilation and that of ICU stay (Song, et al., 2019) . Besides, a meta-analysis of 867 patients with sepsis demonstrated that XBJ treatment improved coagulopathy possibly by decreasing platelet counts, as well as by shortening of activated partial thromboplastin time, prothrombin time, and thrombin time (Hou, Feng, Lin, & Tan, 2015) . In another meta-analysis of case-control studies on sepsis, XBJ was found to significantly reduce 28-day mortality and improve clinical parameters including the APACHE II score, white blood cell count, 

Based on the clinical evidence on XBJ treatment of sepsis, bacterial pneumonia and acute respiratory distress syndrome (ARDS), XBJ was recommended by China's National Health

Commission to treat severe and critical cases of COVID-19, especially during systematic inflammatory response syndrome (SIRS) and/or multi-organ failure("Diagnosis and Treatment

Protocol for Novel Coronavirus Pneumonia (Trial Version 7)," 2020; Song, et al., 2020) . XBJ was used more frequently in severe/critical patients with significant benefits for earlier discharge . XBJ (100 mL, twice per day) combined with routine treatment resulted in significantly reduced IL-6 levels and body temperature in a group of 42 COVID-19 patients . In a retrospective study of 44 COVID-19 patients, XBJ (50 mL XBJ in 100 mL saline, i.v. for 7 days) treatment group (n=22) showed reduced lung inflammation by CT imaging although nucleic acid yet turned negative(C. Zhang, Li, Zhang, Wang, & Jiang) . In a randomized J o u r n a l P r e -p r o o f study of 60 severe COVID-19 patients, low dose (50 mL, twice per day for 7 days) and high dose (100 mL, twice per day for 7 days) of XBJ decreased levels of CRP and erythrocyte sedimentation rate (ESR) compared to routine treatment group while only 100 mL XBJ increased white blood cell count (WBC) (Wen, Zhou, Jiang, & Huang, 2020) . Besides, the APACHE II score after treatment was significantly lower in high dose XBJ group than those in low dose XBJ group and the group with routine treatment (Wen, et al., 2020) . By increasing Th1/Th2 ratio, XBJ injection has been shown to increase the number of Th1 cells in septic rats(S. Zhang, Sun, Wen, & Yin, 2006) . Chen and colleagues reported that XBJ (18 ml/kg, i.p. twice at 0 h and 24 h.) improves survival in response to septic shock in a murine model of polymicrobial sepsis, partially through preventing cytokine storm, inhibiting inflammation and regulating the balance of Tregs and Th17 cells(X. Chen, et al., 2018) . In addition, XBJ has been shown to protect against SARS-CoV-2-induced cell death in virus infected Vero E6 cells, and to reduce the average size and the number of the plaque in a dose dependent fashion (12.5-50 mg/mL)(Q. Ma, et al., 2020) . XBJ was also predicted to treat SARS-CoV-2 infection via modulation of arachidonic acid metabolic pathway (principally used to synthesize inflammatory cytokines, such as MCP-1, TNF, IL, IFN, etc.) by pharmacophore models(Y. Ren, M. C. Yao, et al., 2020) . Kong et al. reported that quercetin, gallic acid, luteolin, rosmarinic acid, rutin, kaempferol hlorogenic acid, tanshinone II A, hydroxysafflor yellow A, and paeoniflorin are the primary active ingredients of XBJ, identified by network pharmacology to be responsible for the treatment effects of XBJ on COVID-19(Y. Kong, et al.) . Hydroxysafflor yellow A, chlorogenic acid and salvianolic acid B were identified as major compositions in XBJ by molecular docking, through "multi-component, multi-target, multi-pathway" pattern to exert protective effects on inflammation and vascular endothelial cell injury (He, Duan, Li, & Zhang, 2020) . Kuxingren,苦杏仁; Shigao,石膏) has been used for the treatment of influenza by disrupting viral surface structure and inhibiting viral entry (Hsieh, et al., 2012) . Overall, LCDD is a recipe of J o u r n a l P r e -p r o o f

Qiao San (银翘散) combination can serve as an alternative treatment for H1N1 infection(C. Wang, et al., 2011) . Time to fever resolution was reduced by 19% with Qseltamivir plus MXSG-Yin

Qiao San treatment, compared to Oseltamivir treatment alone (C. Wang, et al., 2011) . In an experimental study, the transcriptomic analysis of lung tissues of LPS induced pneumonic rats revealed that MXSG regulates multiple complement and coagulation cascades as well as thrombin system to interfere with infection(R. Yang, et al., 2020) . Mechanistically, MXSG has been shown to attenuate host cell entry of influenza virus by regulating PI3K/AKT signaling pathway (Hsieh, et al., 2012) . The second recipe in LCDD, SGMH (射干麻黄汤), is composed of Mahuang (麻黄),

and Xixin (细辛); and is a classical prescription for the treatment of flu-like symptoms, tonsillitis, and asthma . It has been used to treat patients with cough variant asthma (CVA)(H. Wang, et al., 2012) , and shown to downregulate production of Th2/Th17 cells while upregulating CD4+FoxP3+ Tregs cells in asthmatic airway hyperresponsiveness in mice . The third recipe in LCDD, XCH (小柴胡), is composed of Radix Gancao (甘草), Chai Hu (柴胡), Huangqin (黄芩), Banxia (半夏), Shengjiang (生姜), and has been shown to possess antiviral and various anticarcinogenic properties(P. W. Cheng, Ng, & Lin, 2006; N. Zheng, et al., 2013) . XCH has been used to treat chronic hepatitis B(Z. , and found to attenuate liver fibrosis by activating Nrf2 pathway(J. Li, et al., 2017) . The forth recipe in LCDD, WLS (五苓散), is composed of Guizhi (桂枝), Zexie (泽泻), Zhuling (猪苓), Cangshu (苍术), and Fuling (茯苓), and a well-known Chinese prescription for nephritic syndrome, which has been shown to improve kidney excretion function and inhibit inflammatory response(Y. Yang, et al., 2015) . A recent study reported that many water-soluble polysaccharides in LCDD possess J o u r n a l P r e -p r o o f multiple bioactivities of immunomodulation (such as glycyrrhiza polysaccharide promoting the maturation, differentiation and reproduction of immune cells of lymphocytes and macrophages, as well as activating the reticuloendothelial system), anti-inflammation (such as ephedra polysaccharide regulating Factor-1/Smad2 signaling pathway and inhibiting the TLR4 signaling pathway), and anti-oxidation (such as bupleurum polysaccharide reducing the content of MDA in serum and bronchoalveolar lavage fluid (BALF) in models of acute lung injury), as well as antibacterial and antitussive activities .

Among the 6 recipes found most effective in treating patients with COVID-19, LCDD (清肺排毒 汤) is recommended as the primary recipe by the General Office of National Health Commission, China, and the Office of State TCM Administration(2020). Recently, a retrospective study of 63 patients with confirmed COVID-19 showed that the combination of LCDD with Western Medicine exerted significantly better anti-inflammatory effects compared to treatment with Western Medicine alone, in patients with mild and moderate COVID-19 (Xin, et al., 2020) . Combined treatment not only diminished levels of CRP, creatine kinase, creatine kinase-myocardial band, lactate dehydrogenase, and blood urea nitrogen, but also mitigated the extent of multi-organ impairment (Xin, et al., 2020) . In a retrospective study of 98 patients with COVID-19, LCDD treatment relieved symptoms such as fever and cough, normalized laboratory indexes including LYMPH%, CPR, ESR, and reversed pulmonary CT imaging characteristics showing obvious absorption of inflammation, only 6 days after initiation of the treatment(R. .

Four provincial hospitals in China used LCDD to treat 214 patients with COVID-19, following a protocol of 3 days as a course of treatment, and the total effective rate was higher than 90%(K.

Zhang, 2020). Among them, symptoms and CT imaging data of 60% of the patients improved significantly, and 30% of patients had stable symptoms without exacerbation(K. . Coronavirus Pneumonia (Trial Version 7)," 2020). The discharge criteria included were: 1) Body temperature back to normal for more than three days; 2) Respiratory symptoms improve obviously;

3) Pulmonary imaging shows obvious absorption of inflammation, 4) Nucleic acid tested negative twice consecutively from respiratory tract samples such as sputum and nasopharyngeal swabs (sampling interval being at least 24 hours)("Diagnosis and Treatment Protocol for Novel

Coronavirus Pneumonia (Trial Version 7)," 2020). Of note, 96.1% (1,214/1,264, as above) of the patients treated with LCDD satisfied these criteria to be discharged, and no cases deteriorated during treatment (ChinaDaily, 2020b). More recently, in a retrospective multicenter study of 782 confirmed COVID-19 cases from 54 hospitals in 9 provinces of China, Shi et al. reported that early treatment with LCDD at less than 1 week, 1-2 weeks, or 2-3 weeks of onset of symptoms had a higher likelihood of recovery compared to treatment initiated 3 weeks after onset of symptoms(N. Shi, Liu, et al., 2020) . Early LCDD treatment was associated with favorable outcomes, including faster time to recovery, shorter time of viral shedding, and shorter time of hospital stay(N. Shi, Liu, et al., 2020) .

Studies have been carried out to examine inhibitory effects on COVID-19 of active ingredients in LCDD. Network pharmacology analysis conducted by Zhang et al. showed that MXSG in LCDD inhibits SARS-CoV-2 replication, as well as cytokine storm by promoting TH cell differentiation and T cell homeostatic proliferation(Y. Zhang, Yang, He, G., & Li) . Furthermore, through molecular docking prediction, it was found that patchouli alcohol, ergosterol and shionone in LCDD have strong anti-COVID-19 effect(J. L. . Zhou et al identified 87 major bioactive ingredients in LCDD using UHPLC-LTQ-Orbitrap-M, which include 43 flavonoids, 9 alkaloids, 4 triterpenoid saponins, 1 sesquiterpene, 2 coumarins, 10 phenolic acids and 18 other compounds . Another study identified 58 flavonoids, 20 glycosides, 13 carboxylic acids, 7 saponins, 6 alkaloids, 4 terpenes, and other types of compounds by UPLC-Q-TOF/MS(R. Yang, et al., 2020) . In this work, the Toll-like receptor signaling J o u r n a l P r e -p r o o f pathway was shown to play an important role in LCDD induced therapeutic effect on COVID-19(R. Yang, et al., 2020) . Zhao et al. elucidated that baicalin, glycyrrhizic acid, hesperidin and hyperoside are important ingredients and IL6, IL10, TNF-α, AKT1, TP53, PTGS2 and HMOX1 are important targets of LCDD to treat COVID-19(J. . Su et al. found that baicalin and baicalein, active ingredients of Huangqin (黄芩), were the first identified non-covalent, non-peptidomimetic inhibitors of SARS-CoV-2 3CL pro . Baicalin and baicalein were effectively in decreasing the replication of coronaviruses in a cell-based system by interacting with two catalytic residues of 3CL pro (the crucial S1/S2 subsites and the oxyanion loop) to ensconce in the core of the substrate-binding pocket . Liu and Tinglizi (葶苈子), have been used for treating moderate and severe cases (Ang, et al., 2020) .

In addition, Huoxiang (藿香), Lianqiao (连翘), Cangshu (苍术), and Huangqin (黄芩) (the common herbs between QFPD and JHQG) have been frequently used to treat patients of COVID-19 at mild and moderate stages (Ang, et al., 2020) . Notably, Gancao (甘草, the common herb of LHQW, QFPD and JHQG) is among the top 10 herbs/components used most frequently to treat patients at mild, moderate, severe and recovery stages (Ang, et al., 2020) . Network pharmacology analyses indicate that Lianqiao (连翘), Jinyinhua (金银花), Honghua (红花), and Mabiancao (马鞭草) have the most abundant active compounds known to have therapeutic effects on COVID-19, and they may therefore compose the best combination scheme of Chinese herbs/TCM components for COVID-19 treatment .

J o u r n a l P r e -p r o o f Network pharmacology analyses were employed to identify common active ingredients in TCM recipes proven effective for COVID-19 treatment ( Figure 3 ) Niu, et al., 2020) .

Quercetin, glabridin, and gallic acid, active ingredients of the six recipes discussed in Section 2, have been shown to inhibit COVID-19 by downregulating ACE2 (Figure 3) .

Quercetin, ursolic acid, luteolin, and rutin were found to be the common active ingredients of the six recipes discussed in Section 2 that exert therapeutic effects on COVID-19 via modulation of interleukin-6 (IL-6) . Rutin is the unique unique ingredient shared by JHQG, LHQW, HSBD, XFBD, XBJ and LCDD that targets 3CLpro and IL-6 ( Figure 3 ). Glabridin is the common ingredient of JHQG, LHQW, XFBD, HSBD and LCDD that targets ACE2 ( Figure   3 ). Ursolic acid is the unique ingredient shared by all of the six recipes that targets IL-6 ( Figure   3 ). Luteolin is one of the two ingredients shared by all of the six recipes that target ACE2, 3CLpro

and IL-6 ( Figure 3 ). Quercetin is the other ingredient shared by all of the six recipes that targets ACE2, 3CLpro and IL-6 to exert therapeutic effects on COVID-19 ( Figure 3 ). The results of molecular docking analyses indicate that quercetin is one of the top two ingredients (the other one is baicalein) of HSBD, which has high affinity for ACE2(Q. Tao, et al., 2020) . Therefore, quercetin in HSBD may regulate multiple signaling pathways through ACE2, which in turn exert therapeutic effects on COVID-19(Q. Tao, et al., 2020) . The results of molecular docking analyses indicate that quercetin has a high affinity for 3CLpro and ACE2. Quercetin was also predicted to decrease ACE2 expression by downregulating the transcription factors or upregulating miRNAs . Sekiou et al also reported that quercetin exhibits better inhibitory effects on 3CL pro and ACE2 than Hydroxy-Chloroquine using in-silico identification (Sekiou, et al., 2020) .

Therefore, quercetin may represent one of the most important TCM ingredients that have played a major role in mechanistically inhibiting pathophysiological pathways of COVID-19.

Binding to ACE2 is a critical initial step for SARS-CoV-2 to enter into target cells (Hoffmann, et al., J o u r n a l P r e -p r o o f 2020; Lan, et al., 2020) . Therefore, ACE2 is an important therapeutic target for COVID-19 (Monteil, et al., 2020) . Several active ingredients of TCM as discussed above, including quercetin, glabridin, and gallic acid, have been shown to downregulate ACE2 expression by regulating the aforementioned transcription factors (TFs) or miRNAs . The

TFs and miRNAs include hepatocyte nuclear factor 4 alpha (HNF4A), peroxisome proliferator-activated receptor gamma (PPARG), hsa-miR-2113, and hsa-miR-421 .

Network pharmacology analyses and high throughput molecular docking analyses showed that 3-methoxy-glycerol, crude-glycerin and glycyrrhizin B, the active ingredients of JHQG, have strong binding activity for ACE2 (Shen, et al.) . Notably, these analyses revealed that the action mechanism of JHQG might be attributed to its active ingredients of kaempferol, baicalein and oroxylin A, which regulate multiple signaling pathways (such as PTGS1, PTGS2, BCL2, HSP90AB1, HSP90AA1, NCOA2 and CASP3) by binding to ACE2, thereby exerting therapeutic effects on COVID-19 Jimilihan, et al., 2020) . Additional network pharmacology and molecular docking analyses indicate that XFBD inhibits viral invasion and viral replication mainly by binding to ACE2 through flavonoids and phytosterols(H. .

Baicalein and quercetin, the two major active ingredients of HSBD, were predicted by network pharmacology and molecular docking analyses to treat COVID-19 by binding ACE2(Q. Tao, et al., 2020) . The results of molecular docking predictthat quercetin, luteolin, kaempferol, active ingredients from HSBD, physically bind to ACE2 (Lai, et al.) . These findings demonstrate that HSBD exerts therapeutic effects on COVID-19 through ACE2 (Lai, et al.) . In-silico identification results indicated that quercetin, hispidulin, cirsimaritin, sulfasalazine, artemisin and curcumin exhibit potential inhibitory effects on ACE2 (Sekiou, et al., 2020) . Besides, network pharmacology study showed that ACE2 was also targeted by patchouli alcohol from Huoxiang (藿 香), shionone from Ziwan (紫菀), and ergosterol from Zhuling (猪苓)(H. Wu, et al.) . Therefore, ACE2 appears to be one of the major targets for TCM to exert therapeutic effects on COVID-19.

J o u r n a l P r e -p r o o f

Coronavirus 3-chymotrypsin-like protease (known as Mpro, 3CL hydrolase or 3CL pro ) is a three-domain (domains I to III) cysteine protease that is highly conserved among coronaviruses and required for proteolytic maturation of the coronaviruses Elmezayen, Al-Obaidi, Sahin, & Yelekci, 2020; . Besides, 3CL pro has no human homolog . Therefore, 3CL pro is an attractive drug target for coronaviruses including SARS-CoV-2 Elmezayen, et al., 2020; . Su et al found that baicalin and baicalein, active ingredients of Huangqin (黄芩), were the first identified non-covalent, non-peptidomimetic inhibitors of SARS-CoV-2 3CL pro , effective in decreasing the replication of coronaviruses in a cell-based system, by interacting with two catalytic residues (the crucial S1/S2 subsites and the oxyanion loop) of the 3CL pro to ensconce in the core of the substrate-binding pocket . 3CL pro was predicted to be the target of the active ingredients of JHQG (3-methoxy-glycerol, crude-glycerin and glycyrrhizin B,3-methoxy-glycerol, crude-glycerin and glycyrrhizin B) by network pharmacology prediction and high throughput molecular docking analyses (Shen, et al.) . Chlorogenic acid, forsythoside A, and ephedrine were found to be the core active ingredients of JHQG that have strong affinity for 3CL pro by visualization analysis, thereby inhibiting viral replication(Y. Ren, Z. Yin, et al., 2020) . Network pharmacology and molecular docking analyses indicated that flavonoids and phytosterols are the two ingredients in XFBD that inhibit SARS-CoV-2 invasion and replication mainly by binding to 3CL pro , thereby exerting therapeutic effects on COVID-19(H. . Quercetin, luteolin, kaempferol as the active ingredients of HSBD, were predicted to have high affinity for 3CL pro , indicating effects of HSBD on viral replication and maturation. Liu and colleagues found that baicalein and ethanol extract of Huangqin (黄芩), inhibit 3CL pro activity in vitro with activity assay using a peptide substrate (Thr-Ser-Ala-Val-Leu-Gln-pNA) according to the published procedure of SARS-CoV 3CL pro assay(H. Liu, et al., 2021) . Besides, the docking model verified that baicalein binds well to the substrate binding site of 3CL pro (H. Liu, et al., 2021) . The carbonyl group of J o u r n a l P r e -p r o o f baicalein was hydrogen bonded with the E166 backbone amide group of 3CL pro , while catalytic residues H41 and C145 of 3CL pro were well covered by baicalein, accounting for baicalein's inhibitory effect on SARS-CoV-2 via 3CL pro (H. Liu, et al., 2021) . In addition, patchouli alcohol, shionone, and ergosterol from LCDD were all predicted by network pharmacology to treat COVID-19 via targeting of 3CL pro (H. Wu, et al.) . Therefore, 3CL pro may have served as an important target for TCM in preventing the replication and maturation of SARS-CoV-2 to treat COVID-19, and that detailed molecular mechanisms of TCM interacting with 3CL pro for the treatment of COVID-19 warrant further investigation.

Cytokine storm is a hyperactive immune response characterized by release of interferons, interleukins, tumor-necrosis factors, chemokines, and several other mediators, which represents one of the major pathological features of COVID-19 (Sinha, Matthay, & Calfee, 2020) . IL-6, a proinflammatory cytokine, is a key mediator of the acute inflammatory response and the cytokine storm (Sinha, et al., 2020; Turnquist, Ryan, Horikawa, Harris, & Harris, 2020; . Elevation in serum IL-6 levels correlates with ARDS, multi-organ failure, and other adverse clinical outcomes in COVID-19 (Moore & June, 2020) . IL-6 has been shown to be a good biomarker for earlier detection of COVID-19 progression(C. Wang, Fei, Li, Zhao, & Yu, 2020) , and a promising target for the treatment of COVID-19 (Montesarchio, et al., 2020; Sinha, et al., 2020) .

In addition to targeting ACE2 and 3CL pro , TCM has also been shown to modulate IL-6 to relieve COVID-19 symptoms. Network pharmacology was used by Niu et al. to identify the phytochemicals in TCM for the treatment of COVID-19 that regulates IL-6 .

Quercetin, ursolic acid, luteolin, and rutin, active ingredients of the six recipes discussed in Section 2, have been shown to decrease IL-6 levels . Network pharmacology and molecular docking analyses indicate that XFBD may play a role in the treatment of COVID-19 by regulating IL-6 after viral infection of host cells, exerting anti-cytokine storm and anti-oxidation J o u r n a l P r e -p r o o f effects(H. . Analyses applied to identification of molecular targets and mechanisms of HSBD in the treatment of COVID-19 indicate that compound-target network mainly contains 178 compounds and 272 corresponding targets, among which IL-6 is a key target(Q. Tao, et al., 2020) .

TCM has a well-documented history for treating infectious disease. During the fight against COVID-19 in China, six TCM recipes of JHQG, LHQW, XFBD, HSBD, XBJ and LCDD have been shown to be most effective in treating patients with COVID-19. We have systematically reviewed the components, active ingredients, and the potential molecular mechanisms of the 6 TCM recipes in treating COVID-19 and infections by other viruses. The common components/active ingredients among the 6 recipes were also identified to represent most promising drug candidates, characterization of which may result in rapid development of novel therapeutics for the treatment of COVID-19. These ingredients may exert therapeutic effects on COVID-19 via targeting of ACE2, 3CL pro and IL-6. Therefore, the key active ingredients of TCM recipes and their molecular mechanisms driving therapeutic efficacies on COVID-19, warrant in-depth and immediate investigation to help better manage the devastating disease of COVID-19.

This study was supported by National Institute of Health National Heart, Lung and Blood Institute (NHLBI) Grants HL077440 (HC), HL088975 (HC), HL142951 (HC), and HL154754 (HC).

The authors declare that there are no conflicts of interest.

J o u r n a l P r e -p r o o f

Shionone from Ziwan (紫菀, and Ergosterol from Zhuling (猪苓) showed affinity for 3CL pro and ACE2 by network pharmacology analyses

Common Components, Ingredients and Targets of TCM Recipes in Treating COVID-19

Common Components in the Six TCM Recipes Effective for COVID-19 Treatment We compared the herbs/components cross the six most effective recipes of "three TCM decoctions and 3 formulated Chinese medicines" for COVID-19 treatment, and found some common

Herbal medicine and pattern identification for treating COVID-19: a rapid review of guidelines

ClueGO: a Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks

The important role of polysaccharides from a traditional Chinese medicine-Lung Cleansing and Detoxifying Decoction against the COVID-19 pandemic

Protection against COVID-19 injury by qingfei paidu decoction via anti-viral, anti-inflammatory activity and metabolic programming

A Novel Combination of Vitamin C, Curcumin and Glycyrrhizic Acid Potentially Regulates Immune and Inflammatory Response Associated with Coronavirus Infections: A Perspective from System Biology Analysis

Anti-sepsis protection of Xuebijing injection is mediated by differential regulation of pro-and anti-inflammatory Th17 and T regulatory cells in a murine model of polymicrobial sepsis

Statistical evidence for the usefulness of Chinese medicine in the treatment of SARS

Clinical Effectiveness and Case Analysis in 54 NCP Patients Treated with Lanhuaqingwen Granules

Xiao chai hu tang inhibits CVB1 virus infection of CCFS-1 cells through the induction of Type I interferon expression

The Yellow Emperor's Classic of Internal Medicine

Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease

DAVID: Database for Annotation, Visualization, and Integrated Discovery

The Chinese prescription lianhuaqingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function

Clinical Observation of Jinhua Qinggan Granule in Treating Pneumonia Infected by Novel Coronavirus

Drug repurposing for coronavirus (COVID-19): in silico screening of known drugs against coronavirus 3CL hydrolase and protease enzymes

Application of Chinese Medicine in the Management of Critical Conditions: A Review on Sepsis

Identification of a Pharmacological Biomarker for the Bioassay-Based Quality Control of a Thirteen-Component TCM Formula (Lianhua Qingwen) Used in Treating Influenza A Virus (H1N1) Infection

Anti-influenza agents from Traditional Chinese Medicine

Exploring active compounds of jinhua qinggan granules for prevention of covid-19 based on network pharmacology and molecular docking

Xuebijing injection in the treatment of COVID-19: a retrospective case-control study

Potential mechanism of xuebijing injection in treatment of coronavirus pneumonia based on network pharmacology and molecular docking

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Efficacy of Xuebijing for coagulopathy in J o u r n a l P r e -p r o o f patients with sepsis

Mechanism by which ma-xing-shi-gan-tang inhibits the entry of influenza virus

Efficacy of Lianhua Qingwen Compared with Conventional Drugs in the Treatment of Common Pneumonia and COVID-19 Pneumonia: A Meta-Analysis

Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb

Treatment strategies of hospitalized patients with coronavirus disease-19

Qualitative and quantitative analysis of the major constituents in Chinese medical preparation Lianhua-Qingwen capsule by UPLC-DAD-QTOF-MS

Study on the active components in the adjuvant treatment of novel coronavirus pneumonia (covid-19) with jinhua qinggan granules based on network pharmacology and molecular docking

KEGG: kyoto encyclopedia of genes and genomes

Mechanism of XueBiJing Injection on Treatment of Coronavirus Disease

Xiao Chai Hu Tang, a herbal medicine, for chronic hepatitis B

Pharmacological mechanism and network pharmacology research of Huashibaidu formula in treating COVID-19

Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor

Using herbal medicine as a means of prevention experience during the SARS crisis

Treating influenza patients of wind-heat affecting Fei syndrome by jinhua qinggan granule: a double-blinded randomized control trial

Overview of therapeutic drug research for COVID-19 in China

Xiaochaihutang attenuates liver fibrosis by activation of Nrf2 pathway in rats

Efficacy and safety of traditional Chinese medicine for the treatment of influenza A (H1N1): A meta-analysis

The role played by traditional Chinese medicine in preventing and treating COVID-19 in China

Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2)

Effect of combination antiviral therapy on hematological profiles in 151 adults hospitalized with severe coronavirus disease 2019

Network pharmacology for the identification of phytochemicals in traditional Chinese medicine for COVID-19 that may regulate interleukin-6

Shegan-Mahuang Decoction ameliorates asthmatic airway hyperresponsiveness by downregulating Th2/Th17 cells but upregulating CD4+FoxP3+ Tregs

Scutellaria baicalensis extract and baicalein inhibit replication of SARS-CoV-2 and its 3C-like proteasein vitro

BATMAN-TCM: a Bioinformatics Analysis Tool for Molecular mechANism of

Effect of Jinhua Qinggan granules on novel coronavirus pneumonia in patients

Reflections on treatment of COVID-19 with traditional Chinese medicine

Can Chinese Medicine Be Used for Prevention of Corona Virus Disease 2019 (COVID-19)? A Review of Historical Classics, Research Evidence and Current Prevention Programs

The study on the treatment of Xuebijing injection (XBJ) in adults with severe or critical Corona Virus Disease 2019 and the inhibitory effect of XBJ against SARS-CoV-2

Study on Treatment of Influenza A H1N1 Induced Severe Pneumonia by Xuebijing Injection

Inhibition of SARS-CoV-2 Infections in Engineered Human Tissues Using Clinical-Grade Soluble Human ACE2

Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy

Cytokine release syndrome in severe COVID-19

Full text: Diagnosis and Treatment Protocol for COVID-19 Patients

Network Pharmacology Analysis to Identify Phytochemicals in Traditional Chinese Medicines That May Regulate ACE2 for the Treatment of COVID-19. Evid Based Complement Alternat Med, 2020, 7493281. Notice. (2020). Recommendation of combination "Qingfei Paidu Decoction" with Western medicine on treating COVID-19

Potential drugs for the treatment of the novel coronavirus pneumonia (COVID-19) in China

Clinical efficacy of different doses of Jinhuaqinggan granule on influenza and serum levels of cytokines

Traditional Chinese medicine for COVID-19 treatment

Study on treatment of "cytokine storm" by anti-2019-nCoV prescriptions based on arachidonic acid metabolic pathway

Evidence-based complementary and alternative medicine exploring active components and mechanism of jinhua qinggan granules in treatment of covid-19 based on virus-host interaction

TCMSP: a database of systems pharmacology for drug discovery from herbal medicines

In-silico identification of potent inhibitors of covid-19 main protease (mpro) and angiotensin converting enzyme 2 (ace2) from natural products: Quercetin, hispidulin, and cirsimaritin exhibited better potential inhibition than hydroxy-chloroquine against covid-19 main protease active site and ace2

The Potential Molecular Mechanism of Active Compounds Binding SARS-CoV-2 Specific Target Proteins in Huaqing Granules Treat COVID-19 Based on Network Pharmacology and High-Throughput Molecular Docking Fellowship

Xuebijing in the treatment of patients with sepsis

Efficacy and safety of Chinese herbal medicine versus Lopinavir

Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: A retrospective multicenter cohort study

Is a "Cytokine Storm" Relevant to COVID-19?

XueBiJing Injection Versus Placebo for Critically Ill Patients With Severe Community-Acquired Pneumonia: A Randomized Controlled Trial

COVID-19 treatment: close to a cure? A rapid review of pharmacotherapies for the novel coronavirus (SARS-CoV-2)

Discovery of baicalin and baicalein as novel, natural product inhibitors of SARS-CoV-2 3CL protease in vitro. bioRxiv

The Molecular Mechanism of Treating COVID-19 with Huashi Baidu Formula based on Network Pharmacology

Network pharmacology and molecular docking analysis on molecular targets and mechanisms of Huashi Baidu formula in the treatment of COVID-19

Complementary and alternative medicine is expected to make greater contribution in controlling the prevalence of influenza

The potential insights of Traditional Chinese Medicine on treatment of COVID-19

Tu Youyou Biographical

Cytokine Storms in Cancer and COVID-19

Oseltamivir compared with the Chinese traditional therapy maxingshigan-yinqiaosan in the treatment of H1N1 influenza: a randomized trial

IL-6 may be a good biomarker for earlier detection of COVID-19 progression

A network analysis of the Chinese medicine Lianhua-Qingwen formula to identify its main effective components

Montelukast Combined with Shegan Mahuang Tang for Treating of 86 Patients with Cough Variant Asthma

The molecular mechanism of Xuanfei Baidu Formula in the treatment of COVID-19 antiviral effect based on network pharmacology and molecular docking

Clinical observation of qingfeipaidu decoction in the treatment of covid-19

Mechanism of Xuanfei Baidu Tang in treatment of COVID-19 based on network pharmacology

Effect of Xuebijing injection on inflammatory markers and disease outcome of coronavirus disease 2019

Sars: Clinical trials on treatment using a combination of traditional chinese medicine and western medicine

Preliminary exploration of the mechanism of Qingfei Paidu decoction against novel coronavirus pneumonia based on network pharmacology and molecular docking technology

Clinical practice guideline on treating influenza in adult patients with Chinese patent medicines

Network pharmacology and molecular docking analyses on Lianhua Qingwen capsule indicate Akt1 is a potential target to treat and prevent COVID-19

Bioactive natural compounds against human coronaviruses: a review and perspective

Efficacy of Huoxiang J o u r n a l P r e -p r o o f Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial

Curative efficacy and safety of traditional Chinese medicine xuebijing injections combined with ulinastatin for treating sepsis in the Chinese population: A meta-analysis

Study of Molecular Mechanism of Huashibaidu Decoction on COVID-19 Based on Network Pharmacology and Molecular Docking Technology

Clinical retrospective study on the efficacy of Qingfei Paidu decoction combined with Western medicine for COVID-19 treatment

Efficacy of herbal medicine (Xuanfei Baidu decoction) combined with conventional drug in treating COVID-19:A pilot randomized clinical trial

TCMID: Traditional Chinese Medicine integrative database for herb molecular mechanism analysis

Traditional Chinese Medicine in treating influenza A (H1N1)--Jinhua Qinggan granules

Lianhua-Qingwen Displays Antiviral and Anti-Inflammatory Activity and Synergistic Effects with Oseltamivir against Influenza B Virus Infection in the Mouse Model

Chemical composition and pharmacological mechanism of Qingfei Paidu Decoction and Ma Xing Shi Gan Decoction against Coronavirus Disease 2019 (COVID-19): In silico and experimental study

Material Basis Research of Anti-COVID-19 Huashibaidu Granule Gormula

Wuling San protects kidney dysfunction by inhibiting renal TLR4/MyD88 signaling and NLRP3 inflammasome activation in high fructose-induced hyperuricemic mice

Retrospective clinical analysis on treatment of coronavirus disease 2019 with traditional chinese medicine lianhua qingwen

Theoretical Study of the anti-NCP Molecular Mechanism of Traditional Chinese Medicine Lianhua-Qingwen Formula (LQF)

Treatment effects of xuebijing injection in severe septic patients with disseminated intravascular coagulation

Effects of lianhua qingwen granules plus arbidol on treatment of mild corona virus disease-19

Traditional Chinese medicine Lianhua Qingwen treating corona virus disease 2019(COVID-19): Meta-analysis of randomized controlled trials

Xuanfeibaidu Granules is a product of

Clinical observation of Xuebijing in the treatment of COVID-19

Is traditional Chinese medicine useful in the treatment of COVID-19?

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors

Effect of treatment with xuebijing injection on serum inflammatory mediators and th1/2 of spleen in rats with sepsis

Viral and host factors related to the clinical outcome of COVID-19

The Curative Mechanism of Maxingshigan Decoction on Cytokine Storm of COVID-19 Pneumonia Based on

Protocol for developing clinical practice guidelines on traditional Chinese medicine therapy for influenza

Systems pharmacological study illustrates the immune regulation, anti-infection, anti-inflammation, and multi-organ protection mechanism of Qing-Fei

Efficacy of Lianhuaqingwen capsule compared with oseltamivir for influenza A virus infection: a meta-analysis of randomized, controlled trials

Current understanding on antihepatocarcinoma effects of xiao chai hu tang and its constituents

-world study on adverse drug reactions to Xuebijing injection: hospital intensive monitoring based on 93 hospitals (31,913 cases)